New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Allogene Therapeutics, Inc. (ALLO) vs Century Therapeutics, Inc. (IPSC)

Allogene Therapeutics, Inc. and Century Therapeutics, Inc. are both Biotechnology companies. Allogene Therapeutics, Inc. and Century Therapeutics, Inc. are of similar size ($239.7M and $231.1M). Century Therapeutics, Inc. grew revenue faster over the last twelve months: 8,286.7% against −30.4%. Century Therapeutics, Inc. has the higher net margin (−19.1% vs −335,973.6%) and the higher return on invested capital (−71.5% vs −119.4%). Across the 15 metrics below, Century Therapeutics, Inc. leads on 10 and Allogene Therapeutics, Inc. on 5.

Valuation

Metric ALLO IPSC Biotechnology median
P/E n/m n/m 8.49
P/S 45.61 2.10 8.56
P/B 0.55 1.15 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA 0.43 n/m 0.69
EV/Sales (16.66) 1.08 8.00
Earnings yield (101.61%) (55.01%) (35.81%)
Free cash flow yield (50.71%) (35.20%) (25.41%)

Profitability

Metric ALLO IPSC Biotechnology median
Gross margin 100.00% 100.00% 70.18%
Operating margin (342,700.00%) (28.42%) 0.00%
Net margin (335,973.56%) (19.10%) 0.00%
Free cash flow margin (261,473.56%) (99.74%) 0.00%
Return on equity (49.29%) (51.16%) (51.58%)
Return on assets (36.69%) (38.96%) (45.91%)
Return on invested capital (119.37%) (71.47%) 0.00%

Growth

Metric ALLO IPSC Biotechnology median
Revenue growth (TTM) (30.40%) 8,286.72% 7.20%
EPS growth (last fiscal year) 34.09% 91.30% 29.04%
Revenue growth, 5-year CAGR — — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric ALLO IPSC Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.79 8.74 4.79
Net debt to EBITDA 1.24 17.95 1.01

Dividend

Metric ALLO IPSC Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ALLO IPSC Biotechnology median
Market cap 231.06m 239.71m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack